WO2013113942A3 - Novel fusion genes in lung cancer - Google Patents

Novel fusion genes in lung cancer Download PDF

Info

Publication number
WO2013113942A3
WO2013113942A3 PCT/EP2013/052183 EP2013052183W WO2013113942A3 WO 2013113942 A3 WO2013113942 A3 WO 2013113942A3 EP 2013052183 W EP2013052183 W EP 2013052183W WO 2013113942 A3 WO2013113942 A3 WO 2013113942A3
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
patient
cancer
fusion genes
novel fusion
Prior art date
Application number
PCT/EP2013/052183
Other languages
French (fr)
Other versions
WO2013113942A2 (en
Inventor
Lynnette FERNANDEZ-CUESTA
Roman Thomas
Florian Fischer
Johannes Heuckmann
Original Assignee
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. filed Critical MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Publication of WO2013113942A2 publication Critical patent/WO2013113942A2/en
Publication of WO2013113942A3 publication Critical patent/WO2013113942A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The present invention relates to a method for diagnosing lung cancer in a patient, wherein the presence and/or expression of at least one fusion gene in a sample derived from said patient is determined, and wherein the presence or expression of said fusion gene is attributed to the presence of lung cancer in said patient. Furthermore, methods for the selection of susceptibility and/or for the identification of (medical) responders versus non-responders are provided. Also methods for the identification of compounds useful in the medical intervention of cancer, in particular lung cancer, are provided. Accordingly, the present invention also relates to diagnostic means as well as to the medical intervention in proliferative disorders, like cancer and in particular lung cancer.
PCT/EP2013/052183 2012-02-03 2013-02-04 Novel fusion genes in lung cancer WO2013113942A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12153907 2012-02-03
EP12153907.6 2012-02-03

Publications (2)

Publication Number Publication Date
WO2013113942A2 WO2013113942A2 (en) 2013-08-08
WO2013113942A3 true WO2013113942A3 (en) 2013-12-19

Family

ID=47757563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/052183 WO2013113942A2 (en) 2012-02-03 2013-02-04 Novel fusion genes in lung cancer

Country Status (1)

Country Link
WO (1) WO2013113942A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3169809B1 (en) 2014-07-17 2020-04-29 Blueprint Medicines Corporation Prkc fusions
CN107153116A (en) * 2017-06-05 2017-09-12 南通大学附属医院 FNDC3B purposes, the detection method for diagnosing FNDC3B expressions in the kit and lung tissue of adenocarcinoma of lung
CN108486109B (en) * 2018-03-20 2021-07-27 内蒙古大学 Tissue-specific and inducible promoter

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005601A2 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3223104A1 (en) 1982-06-21 1983-12-22 Hoechst Ag, 6230 Frankfurt PHOTOPOLYMERIZABLE MIXTURE AND PHOTOPOLYMERIZABLE COPY MATERIAL MADE THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005601A2 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AL-WADEI HUSSEIN A N ET AL: "Non-genomic inhibitory signaling of beta-carotene in squamous cell carcinoma of the lungs", INTERNATIONAL JOURNAL OF ONCOLOGY, LYCHNIA, GR, vol. 34, no. 4, 1 April 2009 (2009-04-01), pages 1093 - 1098, XP009170181, ISSN: 1019-6439, DOI: 10.3892/IJO_00000236 *
DATABASE EMBL [online] 28 August 1996 (1996-08-28), "Homo sapiens mRNA for KIAA0236 gene, partial cds.", XP002713969, retrieved from EBI accession no. EM_STD:D87073 Database accession no. D87073 *
DATABASE Geneseq [Online] 10 July 2008 (2008-07-10), "DNA fragments of a human Tox gene, 45186.", XP002699653, retrieved from EBI accession no. GSN:ARC01135 Database accession no. ARC01135 *
DATABASE Geneseq [Online] 28 December 2007 (2007-12-28), "Human PTK6 protein sequence SEQ ID NO:79.", XP002713966, retrieved from EBI accession no. GSP:AJU90569 Database accession no. AJU90569 *
DATABASE UniProt [online] 1 October 1996 (1996-10-01), "RecName: Full=Zinc finger protein 142; AltName: Full=HA4654;", XP002713968, retrieved from EBI accession no. UNIPROT:P52746 Database accession no. P52746 *
DATABASE UniProt [Online] 3 March 2009 (2009-03-03), "SubName: Full=ADCY3 protein;", XP002699652, retrieved from EBI accession no. UNIPROT:B7ZLX9 Database accession no. B7ZLX9 *
FAN CHUIFENG ET AL: "Detection of Brk expression in non-small cell lung cancer: clinicopathological relevance.", TUMOUR BIOLOGY : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ONCODEVELOPMENTAL BIOLOGY AND MEDICINE OCT 2011, vol. 32, no. 5, October 2011 (2011-10-01), pages 873 - 880, XP002713967, ISSN: 1423-0380 *
HIDEKI KIMURA ET AL: "ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 75, no. 1, 30 May 2011 (2011-05-30), pages 66 - 72, XP028393807, ISSN: 0169-5002, [retrieved on 20110608], DOI: 10.1016/J.LUNGCAN.2011.05.027 *
HUSSEIN A N AL-WADEI ET AL: "Intercepting neoplastic progression in lung malignancies via the beta adrenergic (-AR) pathway: Implications for anti-cancer drug targets", PHARMACOLOGICAL RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 66, no. 1, 18 March 2012 (2012-03-18), pages 33 - 40, XP028422730, ISSN: 1043-6618, [retrieved on 20120402], DOI: 10.1016/J.PHRS.2012.03.014 *
PEIFER MARTIN ET AL: "Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer", NATURE GENETICS, vol. 44, no. 10, October 2012 (2012-10-01), pages 1104, XP002699655 *
SODA MANABU ET AL: "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 448, no. 7153, 2 August 2007 (2007-08-02), pages 561 - 566, XP002464689, ISSN: 0028-0836, DOI: 10.1038/NATURE05945 *
TIMOFEEVA OLGA A ET AL: "Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 35, no. 4, October 2009 (2009-10-01), pages 751 - 760, XP002699654, ISSN: 1019-6439 *

Also Published As

Publication number Publication date
WO2013113942A2 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
WO2012174256A3 (en) Dna methylation profiles in cancer
WO2012159025A3 (en) Chromosome conformation analysis
WO2013182912A3 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
WO2011151252A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
CA2840149C (en) Methods and nucleic acids for determining the prognosis of a cancer subject
WO2011095623A3 (en) miRNA IN THE DIAGNOSIS OF OVARIAN CANCER
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
WO2013127782A3 (en) Use of micro-rnas or genes as markers for the identification, diagnosis and therapy of individual forms of non-ischemic cardiomyopathies or storage diseases of the heart
IL222252A (en) System, assembly and method for the detection and diagnosis of biological rhythm disorders
EP2901345A4 (en) System for genome analysis and genetic disease diagnosis
WO2012106718A3 (en) Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
WO2012068383A3 (en) ncRNA AND USES THEREOF
WO2007140958A3 (en) Method for identifying whether a patient will be responder or not to immunotherapy
WO2011092285A3 (en) Means and methods for diagnosing heart failure in a subject
WO2012158780A3 (en) Lung cancer signature
WO2011153545A3 (en) Gene expression signature as a predictor of chemotherapeutic response in breast cancer
EP3486657A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
WO2014026768A8 (en) Colorectal cancer markers
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
WO2011156734A3 (en) Method of characterizing vascular diseases
EP2723866A4 (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
WO2014028862A9 (en) Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
WO2013172779A3 (en) Method for indicating the presence or non-presence of prostate cancer
WO2011106541A3 (en) Diagnostic methods involving loss of heterozygosity
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13706936

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13706936

Country of ref document: EP

Kind code of ref document: A2